Skip to navigation Skip to content

News

Share

Multiple Sclerosis Organizations Commit to a Shared Global Research Strategy to Accelerate Cures for MS

June 6, 2023

  • Agreement seeks to coordinate resources on the highest potential research
Multiple sclerosis organizations from Australia, Canada, Denmark, France, Germany, Italy, Spain, the United Kingdom, the United States, and the MS International Federation jointly declared their collective commitment to a global research strategy to cure MS. This commitment will be guided by the Pathways to Cures Roadmap that describes three distinct but overlapping cure pathways: (1) stopping the MS disease process, (2) restoring lost function by reversing damage and symptoms, and (3) ending MS through prevention.

Through the Global Research Strategy Framework, the organizations will:
 
  • Complete a landscape analysis of MS research funding and infrastructure
  • Share national research plans and identify specific areas for collaboration and acceleration
  • Align individual and collective resources and to develop a Global Research Strategy Framework to achieve the greatest impact
  • Create new joint initiatives to address strategic gaps
  • Engage people affected by MS in all aspects of the Global Research Strategy Framework
  • Report on progress together
This commitment was affirmed during the recent Pathways to Cures Global Summit that brought together 200 global leaders from MS advocacy organizations, researchers, doctors, government funders, pharmaceutical companies, supporters and people living with MS. Coordination between MS organizations to develop a global research strategy will effectively address knowledge gaps and avoid duplication to speed progress toward cures together.
 
“MS organizations exist because there are people with MS in every part of the world, and we want a world free of MS. We need everyone to join us,” said Cyndi Zagieboylo, President and CEO, National Multiple Sclerosis Society. “With commitment and focus on a global research strategy, we will achieve MS cures faster. Together is the best way forward.”
 
MS Organizations Endorsing this Statement:
  • Associazione Italiana Sclerosi Multipla (Italian MS Society)
  • Deutsche Multiple Sklerose Gesellschaft (Germany)
  • Esclerosis Múltiple España (Spain)
  • Fondation pour l’Aide à la Recherche sur la Sclérose En Plaques (France)
  • MS Australia
  • MS Canada
  • MS International Federation (Global)
  • MS Society UK
  • National MS Society (U.S.)
  • Scleroseforeningen (Danish MS Society)
 
About Pathways to Cures
Multiple sclerosis (MS) is a growing global health challenge affecting nearly 3 million people worldwide. Tremendous progress has been made in the understanding and treatment of MS over the last several decades, but cures remain elusive. Progress will be hastened by having a roadmap that describes the knowledge gaps, milestones and research priorities leading to cures for everyone with MS.
 
The Pathways to Cures Roadmap was published in 2022 and includes carefully considered recommendations from leaders in MS research and clinical care, as well as people living with MS. The Roadmap is a comprehensive plan to achieve MS cures and has been endorsed by 30 leading MS patient and professional organizations across the globe
 
Research breakthroughs leading to MS cures will require strategic investments in areas of high opportunity and increased multidisciplinary collaboration. The Roadmap is a focal point to coordinate, innovate and optimize research investments.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.

Share


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.